Literature DB >> 27873679

Vancomycin-intermediate resistance in Staphylococcus aureus.

Keiichi Hiramatsu1, Yuki Kayayama2, Miki Matsuo2, Yoshifumi Aiba2, Michie Saito2, Tomomi Hishinuma2, Akira Iwamoto2.   

Abstract

Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor hetero-VISA (hVISA) were discovered almost 20 years ago and have continued to be a stumbling block in the chemotherapy of methicillin-resistant S. aureus (MRSA). Unlike vancomycin resistance mediated by the van gene in enterococci and staphylococci, VISA is generated by accumulation of mutations. It displays diverse and intriguing genetic mechanisms underlying its resistance phenotype. Here we make a brief note on our recent understanding of the genetics of hVISA, VISA and the newly discovered phenotype 'slow VISA' (sVISA). Copyright Â
© 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Pre-hVISA; VISA; Vancomycin; hVISA; rpoB mutation; sVISA

Year:  2014        PMID： 27873679     DOI： 10.1016/j.jgar.2014.04.006

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN： 2213-7165            Impact factor:   4.035


  23 in total

1.  Genetic and Transcriptomic Analyses of Ciprofloxacin-Tolerant Staphylococcus aureus Isolated by the Replica Plating Tolerance Isolation System (REPTIS).

Authors:  Miki Matsuo; Miyu Hiramatsu; Madhuri Singh; Takashi Sasaki; Tomomi Hishinuma; Norio Yamamoto; Yuh Morimoto; Teruo Kirikae; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Novel Potentiators for Vancomycin in the Treatment of Biofilm-Related MRSA Infections via a Mix and Match Approach.

Authors:  Arno Vermote; Gilles Brackman; Martijn D P Risseeuw; Davie Cappoen; Paul Cos; Tom Coenye; Serge Van Calenbergh
Journal:  ACS Med Chem Lett       Date:  2016-11-09       Impact factor: 4.345

3.  Differential Induction of Type I and III Interferons by Staphylococcus aureus.

Authors:  Adeline Peignier; Paul J Planet; Dane Parker
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

4.  Metabolic Mitigation of Staphylococcus aureus Vancomycin Intermediate-Level Susceptibility.

Authors:  Stewart G Gardner; Darrell D Marshall; Robert S Daum; Robert Powers; Greg A Somerville
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Effect of silver nanoparticles on vancomycin resistant Staphylococcus aureus infection in critically ill patients.

Authors:  Saeid Elsawy; Walaa M Elsherif; Rasha Hamed
Journal:  Pathog Glob Health       Date:  2021-04-19       Impact factor: 2.894

6.  Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental Strain.

Authors:  Sabrina Di Gregorio; Silvina Fernandez; Arabela Cuirolo; Olivier Verlaine; Ana Amoroso; Dominique Mengin-Lecreulx; Angela Famiglietti; Bernard Joris; Marta Mollerach
Journal:  Microb Drug Resist       Date:  2016-12-19       Impact factor: 3.431

7.  In Vitro Tolerance of Drug-Naive Staphylococcus aureus Strain FDA209P to Vancomycin.

Authors:  Madhuri Singh; Miki Matsuo; Takashi Sasaki; Yuh Morimoto; Tomomi Hishinuma; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

8.  Vancomycin heteroresistance in Staphylococcus haemolyticus: elusive phenotype.

Authors:  Yamuna Devi Bathavatchalam; Dhanalakshmi Solaimalai; Anushree Amladi; Hariharan Triplicane Dwarakanathan; Shalini Anandan; Balaji Veeraraghavan
Journal:  Future Sci OA       Date:  2021-04-09

9.  Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.

Authors:  Yuki Katayama; Miwa Sekine; Tomomi Hishinuma; Yoshifumi Aiba; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  Semi-quantitative MALDI-TOF for antimicrobial susceptibility testing in Staphylococcus aureus.

Authors:  Tucker Maxson; Cheryl L Taylor-Howell; Timothy D Minogue
Journal:  PLoS One       Date:  2017-08-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.